Remus Pharmaceuticals Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

Remus Pharmaceuticals Limited has informed stock exchanges about a regulatory disclosure. The company filed a certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending September 30, 2026. This document is a standard compliance requirement for listed companies to confirm the accuracy of their shareholding data.

For investors, this update is largely procedural. It confirms that the company has maintained accurate records of its shareholding pattern, including the number of shares held by promoters, FIIs, and public shareholders. While it does not indicate any significant corporate action, it serves as a routine transparency measure to ensure the integrity of the market data available to investors.

Moving forward, investors should monitor the company's regular quarterly earnings reports for more material updates. This disclosure is a standard administrative task and does not, by itself, signal any immediate changes to the company's business operations or financial outlook.